MIT's 35 Innovators Under 35 in Biotech: Nine Rising Stars Shaping the Future

MIT Technology Review Annual List: Spotlight on Innovators Under 35

Every year, MIT Technology Review publishes one of its most anticipated lists — the "35 Innovators Under 35" — identifying the most promising young talents across science and technology. The list focuses on those whose cutting-edge research and technical work have the potential to redefine their respective fields.

This year's list includes nine young innovators from the biotech sector. Their work spans gene therapy, synthetic biology, biopharmaceuticals, and computational biology — collectively pointing toward where the discipline may be headed in the next decade.

Why Young Voices in Biotech Deserve Attention

Biotech is at a critical inflection point. With technologies like CRISPR maturing, AI becoming deeply embedded in drug development, and the cost of gene sequencing continuing to fall, the pace of innovation in this field is accelerating rapidly. And it's often researchers and entrepreneurs in the early stages of their careers who are driving these changes.

Interdisciplinary Convergence as a Catalyst for Breakthroughs

Modern biotech breakthroughs increasingly depend on cross-disciplinary collaboration. The boundaries between computer science, engineering, materials science, and life sciences are blurring. Many of these young innovators bring multidisciplinary backgrounds — they're equally comfortable with wet lab biology and algorithmic modeling or data analysis. That combination of skills is essential for tackling complex biological problems.

From Lab to Industry: The Scientist-Entrepreneur

Unlike previous generations of scientists, today's young innovators think about commercialization and real-world application much earlier in their careers. Many have founded companies while still in graduate school or postdoctoral positions, rapidly translating lab findings into applicable products or therapies. This dual identity — scientist and entrepreneur — is profoundly reshaping the innovation ecosystem in biotech.

Three Core Areas of Breakthrough in Biotech

Gene Therapy and Cell Therapy

Gene therapy and cell therapy are among the most closely watched areas in biotech today. By correcting or replacing disease-causing genes, these approaches hold the promise of fundamentally curing hereditary diseases that were previously considered untreatable. Young researchers are focused on tackling long-standing technical bottlenecks: delivery efficiency, off-target effects, and the high cost of treatment.

Gene delivery is one of the central challenges in gene therapy. The dominant delivery vectors today are adeno-associated viruses (AAV) and lipid nanoparticles (LNP). AAV is widely used for genetic disease treatment due to its low immunogenicity and stable long-term expression, but it has limitations — a constrained payload capacity (around 4.7 kb) and high costs for large-scale production. LNP gained widespread attention following the success of mRNA COVID-19 vaccines and has demonstrated tremendous potential for in vivo nucleic acid delivery. Off-target effects are another key risk: tools like CRISPR can inadvertently cut other genomic sequences similar to the intended target, raising potential oncogenic concerns. The emergence of next-generation base editors and prime editing technologies is dramatically improving editing precision — but how to perform these operations safely and efficiently inside patients remains the central challenge young researchers are racing to solve.

AI-Driven Drug Discovery and Development

The deep integration of artificial intelligence and biotech is reshaping the traditional drug development pipeline. From protein structure prediction to candidate molecule screening, machine learning models are compressing development timelines and reducing the cost of trial and error. Among this cohort of honorees are pioneers who have creatively applied AI methods to the biopharma space.

The landmark moment in protein structure prediction came in 2021 when DeepMind released AlphaFold2, which can predict the three-dimensional structure of nearly any protein with near-experimental accuracy — solving a problem that had challenged structural biology for over 50 years. Previously, resolving a single protein structure via X-ray crystallography or cryo-EM could take years; AlphaFold2 reduced that to minutes. This has directly accelerated the identification and validation of drug targets. At the molecular screening level, generative AI models (such as diffusion models) can design candidate molecules with specific binding activity from scratch — rather than simply searching existing compound libraries — expanding the exploratory space for drug candidates from millions to virtually infinite. Traditional drug development takes an average of more than 10 years from target discovery to clinical trials; AI-assisted development has the potential to compress the early stages by more than 50%, which is a core driver behind the wave of young entrepreneurs entering this space.

Engineering and Scaling Synthetic Biology

The core idea behind synthetic biology is to "program" living systems the way engineers design circuits. By genetically programming cells and microorganisms, researchers can direct them to produce drugs, biofuels, or novel materials. Young innovators in this space are pushing biological manufacturing from proof-of-concept toward scalable production and standardized applications.

The engineering logic of synthetic biology draws on the concept of "standardized components" from electrical engineering: treating genetic functional modules — promoters, ribosome binding sites, coding sequences — as reusable "BioBricks" that can be combined to build genetic circuits with predetermined functions. However, scaling from small-scale lab validation to industrial production faces multiple hurdles: metabolic burden on cells in bioreactors can destabilize engineered circuits, product accumulation may generate toxicity, and maintaining genetic stability across production batches is a persistent challenge. In recent years, the exponential decline in DNA synthesis costs (similar to Moore's Law, roughly a 100-fold decrease per decade) has dramatically lowered the cost of the design-build-test-learn (DBTL) cycle, enabling researchers to test thousands of genetic designs in parallel. This is the technical foundation underpinning the current wave of synthetic biology startups.

Industry Trends Signaled by Young Innovators

The value of this list lies not only in recognizing individual achievement, but in the clear picture it paints of where biotech is headed. The research directions and technical approaches chosen by these under-35 innovators often foreshadow the major breakthroughs biotech will see over the next five to ten years.

For practitioners, investors, and policymakers tracking the evolution of technology, following the work of these young innovators is an important window into how biotech will develop. They are both the practitioners of today and the definers of tomorrow.

As more interdisciplinary talent pours into biotech, there is good reason to expect this field to deliver ever-deeper societal impact — curing disease, improving public health, and advancing sustainable biomanufacturing.